ASBPW
MaterialsAspire Biopharma Holdings Inc - Warrants (18/02/2030)
$0.02+0.00 (+7.88%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ASBPW Today?
No stock-specific AI insight has been generated for ASBPW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.01$0.09
$0.02
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume14K
Avg Volume (10D)—
Shares Outstanding—
ASBPW News
20 articles- Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split RatioYahoo Finance·May 7, 2026
- Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS AcquisitionYahoo Finance·Apr 20, 2026
- Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon ExpoYahoo Finance·Apr 17, 2026
- Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 RevenueYahoo Finance·Apr 16, 2026
- Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail ExpansionYahoo Finance·Apr 15, 2026
- Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail ExpansionYahoo Finance·Mar 19, 2026
- Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales DirectorYahoo Finance·Mar 17, 2026
- Aspire Biopharma Regains Full Compliance with Nasdaq Listing RequirementsYahoo Finance·Feb 20, 2026
- Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of RecordYahoo Finance·Feb 19, 2026
- Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)Yahoo Finance·Dec 2, 2025
- BC-Most Active StocksYahoo Finance·Nov 14, 2025
- Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose AspirinYahoo Finance·Nov 6, 2025
- Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery PlatformYahoo Finance·Oct 6, 2025
- Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025Yahoo Finance·Oct 3, 2025
- Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medicationYahoo Finance·Oct 1, 2025
- Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout ProductYahoo Finance·Sep 17, 2025
- Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout SupplementYahoo Finance·Sep 16, 2025
- Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)Yahoo Finance·Sep 3, 2025
- Sidoti Events, LLC's Virtual August Micro-Cap ConferenceYahoo Finance·Aug 19, 2025
- Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)Yahoo Finance·Aug 18, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.02
Day High$0.00
Day Low$0.00
52 Week High$0.09
52 Week Low$0.01
52-Week Range
$0.01$0.09
$0.02
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume14K
Avg Volume (10D)—
Shares Outstanding—
About Aspire Biopharma Holdings Inc - Warrants (18/02/2030)
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.
Listed February 20, 2025
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—